[Immunotherapy of urothelial neoplasms. Experimental and clinical implications of alpha interferon].
Carballido
J
J
Servicio de Urología, Clínica Puerta de Hierro, Universidad de Alcalá de Henares, Madrid, España.
Alvarez-Mon
M
M
Olivier
C
C
Moltó
L
L
D000283:Administration, Intravesical; D002278:Carcinoma in Situ / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007107:Immune System / Q000187:drug effects; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D007370:Interferon Type I / Q000494:pharmacology / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D011994:Recombinant Proteins; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy*
D007155:Immunologic Factors; D007370:Interferon Type I; D011994:Recombinant Proteins
Inmunoterapia de las neoplasias uroteliales. Implicaciones experimentales y clínicas del interferón alfa.